Show simple item record

dc.contributor.authorSewell, GJ
dc.contributor.authorHong, A
dc.date.accessioned2015-10-27T17:22:30Z
dc.date.available2015-10-27T17:22:30Z
dc.date.issued1997
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.urihttp://hdl.handle.net/10026.1/3747
dc.description.abstract

<jats:p> Objective. This report describes the development and clinical use of a dacarbazine ambulatory infusion for palliative treatment of metastatic malignant mela noma. </jats:p><jats:p> Case Summary. A 39-year-old male with meta static malignant melanoma received ambulatory infu sion of dacarbazine, 2.5 mg/kg/d X 10 days (courses 1 and 2) and 5 mg/kg/d X 10 days (course 3). This was made possible by the development of a modified dacarbazine infusion formulation which increased drug stability. The first two courses were well toler ated and the patient remained independent and ac tive. A pilot pharmacokinetic study was undertaken on the third course to enable comparison of the potential exposure of tissues to dacarbazine between the prolonged infusion and conventional schedules. </jats:p><jats:p> Discussion. Under conditions replicating ambu latory infusion (37°C) the modified infusion of dacar bazine was stable for 24 hours (92.4% remaining) compared with a standard infusion in water for injection (89.2% remaining after 8 hours). The patient appeared to benefit from ambulatory treatment, and mild nausea was the only adverse effect recorded during the first two treatment courses. The pharma cokinetic study revealed an average steady-state plasma concentration (Cpss<jats:sub>ave</jats:sub> ) and AUC of 243 ng · mL<jats:sup>-1</jats:sup> and 58.4 μg · h·mL <jats:sup>-1</jats:sup>, respectively. </jats:p><jats:p> Conclusion. Ambulatory infusion of dacarba zine in the home setting is possible with the modified infusion formulation described in this report. </jats:p>

dc.format.extent47-49
dc.languageen
dc.language.isoen
dc.publisherSAGE Publications
dc.subjectCancer
dc.titleAmbulatory infusion of dacarbazine for metastatic malignant melanoma: A clinical, pharmaceutical and pharmacokinetic case report
dc.typejournal-article
dc.typeArticle
plymouth.issue1
plymouth.volume3
plymouth.publication-statusPublished
plymouth.journalJournal of Oncology Pharmacy Practice
dc.identifier.doi10.1177/107815529700300107
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Health Professions
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy MANUAL
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Users by role
dc.identifier.eissn1477-092X
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1177/107815529700300107
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV